| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.063 | 0.05 |
| mRNA | (5Z)-7-Oxozeaenol | GDSC1000 | pan-cancer | AAC | 0.061 | 0.05 |
| mRNA | SR1001 | CTRPv2 | pan-cancer | AAC | -0.076 | 0.05 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.072 | 0.05 |
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | 0.075 | 0.05 |
| mRNA | ML083 | CTRPv2 | pan-cancer | AAC | -0.077 | 0.05 |
| mRNA | T0901317 | GDSC1000 | pan-cancer | AAC | -0.064 | 0.06 |
| mRNA | CHIR-99021 | GDSC1000 | pan-cancer | AAC | 0.062 | 0.06 |
| mRNA | AZD7762 | GDSC1000 | pan-cancer | AAC | 0.063 | 0.06 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.11 | 0.06 |